Prime Medicine (PRME) announced that Keith Gottesdiener has decided to step down as CEO and a member of the Company’s Board of Directors, effective immediately. Allan Reine, M.D., Prime Medicine’s CFO, has been named CEO and member of the Board of Directors and Jeff Marrazzo, member of the Company’s Board of Directors, has been named Executive Chair.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Prime Medicine to deprioritize CGD programs, reduce headcount by 25%
- Prime Medicine announces initial data from Phase 1/2 study of PM359
- Prime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a Buy
- Prime Medicine, Inc.: Buy Rating Backed by Promising Gene Editing Advancements and Robust Pipeline
- Prime Medicine Reports Q1 2025 Financial Results